Biotech Values

[jq1234]

I know there are many who disagree, but I think it is wrong. We’ll see soon enough where other big biopharma stand in this debate. I assume inclisiran hit CVOT, but magnitude is uncertain. There is no way I would bet it reaches 25% based on the other 2 PCSK9 CVOTs. Now has to take consideration Vascepa can somewhat impact trial result, don’t think they can really exclude some people who are going to take Vascepa.